Understanding the Market | ALPHAMAB-B rose over 7% after announcing plans for an on-market share buyback, with the market focusing on the significant data from the ESMO conference

ALPHAMAB-B rose over 7%, as of the time of writing, it increased by 6.79%, trading at HKD 14.63, with a transaction volume of HKD 37.113 million. In terms of news, ALPHAMAB announced that on October 16, the company spent HKD 5.483 million to repurchase 400,000 shares. The company previously announced that, based on the general authorization granted to the board (share repurchase authorization approved by shareholders at the annual general meeting on June 12, 2025), the board resolved on October 12, 2025, to repurchase the company's ordinary shares from the open market from time to time, with a maximum repurchase amount of HKD 20 million. In addition, the 2025 European Society for Medical Oncology (ESMO) will be held in Berlin, Germany, from October 17 to 21, and the latest research abstracts will be announced on the day of the presentation. It is reported that 23 studies from China have been selected for LBA, including key studies such as ALPHAMAB's KN026